drugset
drugset / Trial / NCT01892891

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

NCT01892891 ↗

Phase 1 Completed 40 enrolled Virobay Inc.
RandomizedSingle-groupTriple-blindTreatment

Summary

VBY-036 may treat or prevent nerve pain. This study aims to find the highest safe and tolerable dose of VBY-036 in healthy volunteers. Volunteers will be randomly selected to receive either a placebo or VBY-036 (30, 100, 300, 600 or 900 mg) once daily for seven days in a row.

Timeline

Start
2013-07
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject VBY-036 Unknown 30 mg Oral
Subject VBY-036 Unknown 100 mg Oral
Subject VBY-036 Unknown 300 mg Oral
Subject VBY-036 Unknown 600 mg Oral
Subject VBY-036 Unknown 900 mg Oral

Indications

No indication recorded.